CJC-1295

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is CJC-1295?

If your query is what is CJC-1295, the practical answer is: CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile growth hormone (GH) secretion from the anterior pituitary. It is one of the most widely discussed CJC-1295 peptide compounds in GH-axis research contexts.[1][2]

In the landmark human study, Teichman et al. (2006) demonstrated that a single dose of CJC-1295 produced sustained 2- to 10-fold increases in GH concentration and 1.5- to 3-fold increases in IGF-1 levels, with effects persisting for up to 6 days after injection. After multiple doses, mean IGF-1 levels increased by 1.5- to 3-fold for 9 to 11 days.[1] This prolonged duration distinguishes CJC-1295 from shorter-acting GHRH analogs like Sermorelin.

Importantly, Ionescu & Bhatt (2006) confirmed that pulsatile GH secretion is preserved during continuous CJC-1295 stimulation, meaning the compound works within the body’s natural secretory rhythm rather than overriding it.[2] This pulsatility preservation is a key pharmacological advantage over exogenous GH administration.

For context across the GH-axis peptide class, this page pairs naturally with Ipamorelin (a GH secretagogue that works via the ghrelin receptor rather than GHRH), Sermorelin (a shorter-acting GHRH analog), and Tesamorelin (a GHRH analog with FDA approval for HIV-associated lipodystrophy).

Compound Profile

What Does CJC-1295 Actually Do?

CJC-1295 peptide stimulates the anterior pituitary to release growth hormone in a pulsatile pattern that mirrors natural GH secretion. The practical effect is an elevated GH/IGF-1 baseline over days rather than hours, which is why CJC-1295 is typically evaluated by multi-week trend quality rather than acute single-dose response.[1][2]

Key findings from human and preclinical data:

• Sustained GH elevation: 2- to 10-fold increases in GH concentration persisting for up to 6 days after a single injection in healthy adults.[1]
• IGF-1 amplification: 1.5- to 3-fold increases in IGF-1 levels sustained for 9 to 11 days after multiple doses, indicating cumulative signalling.[1]
• Pulsatility preservation: unlike exogenous GH, CJC-1295 maintains the body’s natural pulsatile GH secretion pattern, which is considered physiologically important for downstream signalling quality.[2]
• Serum protein profile changes: Sackmann-Sala et al. (2009) documented measurable changes in serum protein profiles in healthy subjects following CJC-1295 administration, suggesting broader systemic effects beyond isolated GH elevation.[3]
• GRF receptor activation: the parent sequence GRF(1-29) activates the GHRH receptor on the anterior pituitary with high specificity, and CJC-1295’s modifications extend this activation window.[4]

The practical interpretation framework: CJC-1295 creates a more favourable GH signalling environment over time. Whether that translates into measurable recovery, body composition, or sleep benefits depends on baseline conditions, training structure, and how consistently fundamentals are controlled.

How CJC-1295 Works

CJC-1295 is a modified version of the first 29 amino acids of growth hormone-releasing hormone (GHRH, also called GRF 1-29). The modifications serve two purposes: protecting the peptide from enzymatic degradation (DPP-IV cleavage) and, in the DAC version, enabling covalent binding to serum albumin for extended half-life.[1][4]

The mechanism operates through a well-characterised pathway:

• GHRH receptor binding: CJC-1295 binds the GHRH receptor on somatotroph cells in the anterior pituitary, triggering intracellular cAMP signalling that stimulates GH synthesis and release.[4][5]
• Pulsatile release preservation: the hypothalamic-pituitary feedback loop remains intact during CJC-1295 stimulation, meaning GH is released in pulses rather than continuous elevation. This is pharmacologically significant because pulsatile GH is more effective at driving IGF-1 production and downstream tissue effects than continuous GH exposure.[2]
• IGF-1 cascade: elevated GH stimulates hepatic IGF-1 production, which mediates many of the anabolic, recovery, and body composition effects attributed to the GH axis.[1][3]
• Somatostatin sensitivity retained: CJC-1295 does not override somatostatin (the GH-inhibiting hormone), meaning the body’s natural braking system remains functional. This contrasts with approaches that bypass pituitary regulation entirely.[2][5]

The engineering distinction matters: CJC-1295’s longevity comes from modified amino acids (to resist DPP-IV degradation) and, in the DAC formulation, a Drug Affinity Complex that binds albumin. This extends the effective half-life from minutes (native GHRH) to days.[1][4]

Muscle Growth and Body Recomp Context

Muscle growth and body recomposition relevance for CJC-1295 operates through the GH/IGF-1 axis. Elevated IGF-1 supports protein synthesis, nitrogen retention, and recovery from training-induced muscle damage — but these effects are indirect and baseline-dependent.[1][3]

The evidence context for GH-axis stimulation and body composition:

• IGF-1 and muscle protein synthesis: the 1.5- to 3-fold IGF-1 increases documented with CJC-1295 are within the range associated with improved recovery and anabolic signalling in GH-axis research.[1]
• Tesamorelin precedent: the closely related GHRH analog tesamorelin has demonstrated measurable body composition changes (reduced visceral fat) in clinical trials, providing directional evidence that GHRH-pathway stimulation can influence body composition.[8]
• Age-related GH decline: GH secretion decreases approximately 14% per decade after age 30. GHRH analogs like CJC-1295 are studied as potential interventions for this somatopause decline, particularly for body composition maintenance in aging populations.[6][7]

Practical interpretation: CJC-1295 is more accurately framed as a recovery and body-composition support compound than a direct muscle-building agent. Outcomes are typically most visible when training, nutrition, and sleep fundamentals are stable and tracked across multi-week blocks. For the Fat Loss & Recomp goal specifically, the GH-axis contribution is primarily through improved recovery quality and metabolic support rather than direct lipolysis.

Hormonal Support Context

Testosterone and hormonal support relevance for CJC-1295 is indirect. CJC-1295 acts on the GH axis specifically, not the hypothalamic-pituitary-gonadal (HPG) axis that governs testosterone production.[1][5]

However, GH and testosterone systems interact: adequate GH signalling supports overall endocrine environment quality, and the recovery and sleep improvements associated with GH-axis optimisation can indirectly support hormonal balance. Sattler (2013) reviewed the interplay between GH decline and broader hormonal changes in aging males, noting that GH-axis intervention may support overall endocrine resilience even when testosterone-specific effects are not the primary mechanism.[6]

The honest framing: CJC-1295 is a GH-axis compound with possible indirect hormonal environment benefits. It is not a testosterone replacement or direct androgenic agent.

Longevity and Healthy Aging Context

Longevity and healthy aging is where CJC-1295 intersects with the broader somatopause literature. The age-related decline in GH secretion is well-documented and associated with increased body fat, decreased lean mass, reduced bone density, and impaired recovery capacity.[6][7][9]

Key context from the aging literature:

• Somatopause: GH secretion declines approximately 14% per decade from age 30, with corresponding reductions in IGF-1. This decline is associated with sarcopenia, increased adiposity, and reduced functional capacity.[6][7]
• GHRH analog rationale: Merriam et al. (1997, 2003) argued that GHRH analogs and GH secretagogues represent a more physiological approach to addressing somatopause than exogenous GH, because they preserve pulsatile secretion patterns and hypothalamic-pituitary feedback.[7][9]
• Safety review: Sigalos & Pastuszak (2018) reviewed the safety and efficacy of GH secretagogues as a class, concluding that they offer a potentially safer alternative to exogenous GH for age-related GH decline, though noting that long-term human safety data remains limited.[5]

Interpretation for CJC-1295 specifically: the compound’s pulsatility preservation and sustained IGF-1 elevation make it one of the more pharmacologically interesting GHRH analogs for longevity-oriented research. But “anti-aging” claims should stay evidence-weighted: the rationale is strong, the mechanism is sound, but large-scale long-term human outcome data is not yet available.

Recovery and Sleep Context

Recovery and sleep relevance for CJC-1295 is biologically grounded: the majority of natural GH secretion occurs during slow-wave sleep. By amplifying GH pulsatility, CJC-1295 may enhance the recovery value of sleep without necessarily changing sleep architecture itself.[2][5]

The practical signal is usually reported as improved recovery feel upon waking, better training readiness, and fewer disrupted training blocks. These are indirect outcomes mediated through GH/IGF-1 elevation rather than direct sedative or sleep-promoting effects.

When evaluating recovery claims, the most reliable approach is tracking recovery quality across consistent sleep schedules over multiple weeks. Single-night impressions are unreliable due to the many confounding variables that affect sleep quality independently of GH axis status.

CJC-1295 Benefits

CJC-1295 benefits are best understood through the evidence hierarchy:

• Sustained GH/IGF-1 elevation: the most directly demonstrated benefit, with 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases documented in human subjects.[1]
• Preserved pulsatile secretion: unlike exogenous GH, CJC-1295 maintains natural GH pulse patterns, which is pharmacologically significant for downstream signalling quality.[2]
• Extended duration of action: the DAC version provides days of sustained activity from a single injection, reducing administration frequency compared to shorter-acting GHRH analogs.[1][4]
• Recovery support: improved recovery quality and training continuity reported in practical contexts, mediated through GH/IGF-1-dependent tissue repair pathways.[5][10]
• Body composition support: indirect support for lean mass maintenance and fat reduction through improved GH axis signalling, with GHRH-analog class evidence from tesamorelin trials providing directional support.[8]
• Aging-related GH decline mitigation: the somatopause literature supports GHRH analog use as a more physiological approach to age-related GH decline than exogenous GH.[6][7][9]

Evidence-weighted read: GH/IGF-1 elevation is well-documented in humans. Downstream clinical outcomes (body composition, recovery, aging) are supported by mechanism and class-level evidence but lack large-scale CJC-1295-specific outcome trials. Benefits of CJC-1295 are strongest when fundamentals are stable and outcomes are judged by trend quality over weeks.[1][5]

CJC-1295 Side Effects

For CJC-1295 side effects intent, the safety profile draws from the Teichman human study and broader GH secretagogue class data:

• Injection site reactions: redness, swelling, or irritation at injection sites. The most commonly reported adverse effect in the Teichman study.[1]
• Water retention: transient fluid retention and puffiness, consistent with elevated GH/IGF-1 activity. Usually resolves with hydration management.
• Headache: reported in some subjects during clinical evaluation.[1]
• Flushing or warmth: transient post-injection flushing reported in some users.
• Appetite changes: GH axis stimulation can influence appetite patterns, though direction and magnitude vary considerably between individuals.
• Glucose handling concerns: GH has known insulin-antagonistic effects. Sigalos & Pastuszak (2018) noted that glucose metabolism monitoring is appropriate with GH secretagogue use, particularly in metabolically sensitive populations.[5]
• Person-to-person variability: individual responses vary substantially. Attribution is difficult when multiple variables (training, nutrition, sleep) change simultaneously.

The Teichman study reported CJC-1295 was generally well tolerated, with adverse events mostly mild and injection-site-related.[1] Sigalos & Pastuszak’s 2018 review concluded that GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance.[5] Weekly trend logging is more reliable than single-day reactions when assessing side effect significance.

Half-Life

For CJC-1295 half-life queries: the half-life varies significantly depending on DAC status.

• CJC-1295 with DAC: approximately 5 to 8 days, owing to covalent albumin binding via the Drug Affinity Complex. This is the version used in the Teichman et al. study, which showed GH effects persisting for up to 6 days after a single dose.[1][4]
• CJC-1295 without DAC (Mod GRF 1-29): approximately 30 minutes. The DPP-IV-resistant amino acid modifications extend the half-life beyond native GHRH (which degrades in under 10 minutes) but without albumin binding, clearance remains relatively rapid.

For comparison: native GHRH has a half-life under 10 minutes. Sermorelin (GRF 1-29 without modifications) has a similarly short half-life. CJC-1295 with DAC represents a roughly 500-fold increase in persistence over native GHRH.[1][4]

Practical takeaway: use half-life as orientation for administration frequency planning, but judge outcomes by weekly recovery and output trends rather than strict pharmacokinetic clock assumptions.

CJC-1295 and Ipamorelin Combination Context

CJC-1295 and Ipamorelin (also searched as CJC-1295 Ipamorelin and CJC 1295 ipamorelin) is one of the most discussed peptide combinations in the GH-axis space. The rationale is pharmacologically sound: the two compounds stimulate GH release through distinct receptor pathways.

• CJC-1295: activates the GHRH receptor on pituitary somatotrophs → signals GH synthesis and release.[1][4]
• Ipamorelin: activates the ghrelin receptor (GHS-R) on somatotrophs → amplifies GH pulse amplitude without affecting other hormone axes (unlike older GH secretagogues like GHRP-6 that also influence cortisol and prolactin).[5][10]

The combination is discussed as potentially synergistic because GHRH-pathway and ghrelin-pathway stimulation are known to produce greater GH release together than either pathway alone.[5] In practical contexts, CJC-1295 ipamorelin benefits discussions typically centre on enhanced recovery quality, improved sleep-linked GH pulsatility, and more consistent training readiness.

Important caveats: no published clinical trial has specifically studied CJC-1295 + Ipamorelin in combination. The synergy rationale is extrapolated from pathway-level pharmacology and class-level GH secretagogue data. See CJC-1295 vs Ipamorelin for the full comparison breakdown.

Limits of Current Evidence

• Human pharmacokinetic and pharmacodynamic data is solid for CJC-1295 with DAC, thanks to the Teichman (2006) and Ionescu (2006) studies. GH/IGF-1 elevation in humans is well-documented.[1][2]
• Clinical outcome data is limited. No large-scale trials have evaluated CJC-1295 for specific clinical endpoints (body composition, recovery, aging). Most outcome evidence comes from class-level GHRH analog data and the tesamorelin precedent.[8]
• CJC-1295 without DAC (Mod GRF 1-29) has minimal published clinical data. Most formal research uses the DAC version. No-DAC pharmacology is largely extrapolated from the parent GRF 1-29 sequence.
• Combination protocols (CJC-1295 + Ipamorelin) lack dedicated clinical trials. Synergy claims are mechanistically reasonable but clinically unconfirmed.
• Long-term safety surveillance is absent. The Teichman study was short-duration. Sigalos & Pastuszak’s safety review is encouraging but acknowledges the need for longer follow-up.[1][5]
• DAC vs no-DAC discussions are often over-simplified. The choice involves pharmacokinetic trade-offs, not categorical superiority.[1]

Decision rule: confidence is highest for GH/IGF-1 elevation in humans. Confidence decreases progressively for specific clinical outcomes, long-term safety, and combination protocol effects.

Verdict

CJC-1295 is one of the best-characterised GHRH analogs in the peptide research space, with human pharmacokinetic data demonstrating sustained GH/IGF-1 elevation and preserved pulsatile secretion. The compound has clear pharmacological advantages over both native GHRH (too short-lived) and exogenous GH (bypasses pituitary regulation).[1][2]

Where it fits: GH-axis support for recovery continuity, body composition maintenance, and aging-related GH decline contexts. It is not a fast-acting transformation agent — value is typically judged by trend quality across multi-week blocks when fundamentals (sleep, training, nutrition) are stable.

For navigation, map this profile to Muscle Growth, Fat Loss & Recomp, Longevity / Healthy Aging, and Hormonal Support. Pressure-test with CJC-1295 vs Ipamorelin and CJC-1295 vs Sermorelin, and cross-reference with Tesamorelin for the FDA-approved GHRH analog comparison and GHRP-2 for an alternative secretagogue pathway.

FAQ

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates pulsatile GH secretion from the anterior pituitary. In human studies, it produced sustained 2- to 10-fold GH increases and 1.5- to 3-fold IGF-1 increases lasting up to 6-11 days. It is one of the most studied GHRH analogs in the peptide research space.[1][2]

What does CJC-1295 peptide do?

CJC-1295 activates the GHRH receptor on pituitary somatotroph cells, triggering growth hormone synthesis and release while preserving natural pulsatile secretion patterns. The elevated GH drives hepatic IGF-1 production, which mediates downstream effects on recovery, body composition, and tissue repair.[1][2][3]

CJC-1295 with DAC vs without DAC: what is the practical difference?

The DAC (Drug Affinity Complex) enables covalent albumin binding, extending the half-life from ~30 minutes (no-DAC) to 5-8 days (with DAC). Both activate the same GHRH receptor. DAC provides sustained elevation with less frequent dosing; no-DAC provides sharper, shorter GH pulses. Neither is categorically superior — the choice depends on the research context.[1][4]

What are CJC-1295 benefits?

Documented benefits include sustained GH/IGF-1 elevation (2-10x GH, 1.5-3x IGF-1), preserved pulsatile secretion, extended duration of action, and potential support for recovery, body composition, and age-related GH decline. Downstream clinical benefits are supported by mechanism and class-level evidence but lack large-scale CJC-1295-specific outcome trials.[1][5][6]

What are CJC-1295 side effects?

Commonly reported side effects include injection site reactions, transient water retention, headache, flushing, and appetite changes. The Teichman study reported the compound was generally well tolerated. Glucose metabolism monitoring is appropriate with GH secretagogue use. Person-to-person variability is substantial.[1][5]

CJC-1295 dose and CJC-1295 dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Dose and dosage intent is valid, but this profile focuses on mechanism context, evidence quality, and risk-aware interpretation. Refer to primary research literature for protocol parameters.

CJC-1295 vs Ipamorelin: why compare them?

CJC-1295 works via the GHRH receptor; Ipamorelin works via the ghrelin receptor (GHS-R). They stimulate GH through distinct pathways, which is why their combination is frequently discussed. No combination clinical trial exists, but the pharmacological rationale for synergy is sound. See CJC-1295 vs Ipamorelin.[5]

CJC-1295 vs Sermorelin: what is the useful decision angle?

Both are GHRH analogs, but CJC-1295 has amino acid modifications that resist enzymatic degradation and (with DAC) albumin binding for extended half-life. Sermorelin uses the native GRF(1-29) sequence with a very short half-life. CJC-1295 offers longer duration; Sermorelin has a longer clinical history. See CJC-1295 vs Sermorelin.

Is CJC-1295 safe?

The Teichman human study reported CJC-1295 was generally well tolerated with mostly mild injection-site adverse events. Sigalos & Pastuszak’s 2018 review concluded GH secretagogues as a class have acceptable safety profiles, while noting the need for longer-term surveillance. Long-term safety data specific to CJC-1295 remains limited.[1][5]

What is the CJC-1295 half-life?

With DAC: approximately 5-8 days (due to albumin binding). Without DAC (Mod GRF 1-29): approximately 30 minutes. For comparison, native GHRH has a half-life under 10 minutes. The DAC version represents roughly a 500-fold increase in persistence over native GHRH.[1][4]

Where does CJC-1295 map inside site goal pathways?

Most commonly to Muscle Growth, Fat Loss & Recomp, Longevity / Healthy Aging, and Hormonal Support. Interpreted with a trend-first, fundamentals-dependent lens rather than acute-effect expectations.

Is CJC-1295 the same as Modified GRF 1-29?

Not exactly. Modified GRF 1-29 (Mod GRF 1-29) refers to CJC-1295 without DAC — it has the same amino acid modifications for DPP-IV resistance but lacks the Drug Affinity Complex for albumin binding. CJC-1295 with DAC and Mod GRF 1-29 share the same core sequence but differ in half-life and administration characteristics.[1][4]

References

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683.
2. Ionescu M, Bhatt DL. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792-4797. PMID: 17018654.
3. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009;19(6):471-477. PMID: 19386527.
4. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. PMID: 15817669.
5. Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207.
6. Sattler FR. Growth hormone in the aging male. Best Pract Res Clin Endocrinol Metab. 2013;27(4):541-555. PMID: 24054930.
7. Merriam GR, et al. Growth hormone-releasing hormone and growth hormone secretagogues in normal aging. Endocrine. 2003;22(1):41-48. PMID: 14610297.
8. Badran AS, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin, a GHRH analogue, in HIV-associated lipodystrophy: a systematic review and meta-analysis. Obes Res Clin Pract. 2026;20(1):1-12. PMID: 41545261.
9. Merriam GR. Potential applications of GH secretagogs in the evaluation and treatment of the age-related decline in growth hormone secretion. Endocrine. 1997;7(1):49-52. PMID: 9449031.
10. Mayfield CK, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026;54(1):223-229. PMID: 41476424.